KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $193.4 million.

  • BeOne Medicines' Cash from Financing Activities rose 7491.79% to $961.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $958.0 million, marking a year-over-year increase of 75.77%. This contributed to the annual value of $193.4 million for FY2024, which is 53.55% down from last year.
  • According to the latest figures from FY2024, BeOne Medicines' Cash from Financing Activities is $193.4 million, which was down 53.55% from $416.5 million recorded in FY2023.
  • BeOne Medicines' 5-year Cash from Financing Activities high stood at $5.2 billion for FY2020, and its period low was -$19.0 million during FY2022.
  • Over the past 3 years, BeOne Medicines' median Cash from Financing Activities value was $193.4 million (recorded in 2024), while the average stood at $197.0 million.
  • As far as peak fluctuations go, BeOne Medicines' Cash from Financing Activities surged by 5,972.39% in 2020, and later tumbled by 100.54% in 2022.
  • BeOne Medicines' Cash from Financing Activities (Yearly) stood at $5.2 billion in 2020, then slumped by 32.03% to $3.5 billion in 2021, then crashed by 100.54% to -$19.0 million in 2022, then surged by 2,295.34% to $416.5 million in 2023, then tumbled by 53.55% to $193.4 million in 2024.